Neurocrine Biosciences, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for neurological and endocrine-related disorders. The company was founded in 1992 and is headquartered in San Diego, California. Since its inception, Neurocrine Biosciences has been dedicated to advancing the understanding of the brain and developing novel treatments for patients in need.
Neurocrine Biosciences is primarily focused on researching and developing drugs that target the central nervous system and related disorders. They have expertise in areas such as neurology, psychiatry, and endocrinology. The company's portfolio includes both small molecule drugs and biologic agents designed to address a wide range of neurological and endocrine conditions.
Neurocrine Biosciences is responsible for developing Ingrezza (valbenazine), which is the first FDA-approved treatment for adults with tardive dyskinesia, a condition characterized by involuntary movements of the face and body. Ingrezza works by selectively inhibiting the vesicular monoamine transporter 2 (VMAT2) to reduce the excessive dopamine release that contributes to the symptoms of tardive dyskinesia. The approval of Ingrezza marked a significant milestone for Neurocrine Biosciences and provided a much-needed treatment option for patients suffering from this debilitating condition.
Neurocrine Biosciences is listed on the NASDAQ stock exchange under the ticker symbol "NBIX." The company has experienced steady growth and success in the biopharmaceutical industry, driven by its commitment to scientific innovation and dedication to improving patient outcomes. They have a strong pipeline of investigational drugs targeting various disorders, including Parkinson's disease, uterine fibroids, and congenital adrenal hyperplasia.
The company's success can be attributed to its collaborative approach to drug development, partnering with academic institutions, research organizations, and other industry leaders. Neurocrine Biosciences actively seeks strategic collaborations to advance its research and bring innovative therapies to market. This approach allows them to leverage expertise and resources to accelerate the development of promising drug candidates.
Neurocrine Biosciences is recognized for its contributions to the field of neuroscience and its commitment to addressing unmet medical needs. Through their research and development efforts, the company strives to improve the lives of patients with neurological and endocrine disorders. With a strong focus on innovation and a growing pipeline of potential therapies, Neurocrine Biosciences continues to make significant contributions to the advancement of neuroscience and patient care.